Recent advancements in the treatment of epithelial ovarian cancer

被引：8

作者：

DiSaia, PJ ^{[1
]}

Tewari, KS ^{[1
]}

机构：

[1] Univ Calif Irvine, Ctr Med, Div Gynecol Oncol, Chao Family NCI Designated Comprehens Canc Ctr, Orange, CA 92868 USA

来源：

JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH | 2001年 / 27卷 / 02期

关键词：

ovarian cancer; chemotherapy; management;

D O I：

10.1111/j.1447-0756.2001.tb01223.x

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

bImportant advances in the management of advanced epithelial ovarian cancer have been made in recent years, with much of the knowledge emanating from clinical trials conducted by the Gynecological Oncology Group (GOG). This monograph reviews the trials that have defined current clinical practice and summarizes some innovative techniques and promising new drugs for the future.

引用

收藏

页码：61 / 75

页数：15

相关论文

共 75 条

[31] PHASE-I TRIAL OF INTRAPERITONEAL TAXOL - A GYNECOLOGIC ONCOLOGY GROUP-STUDY [J].

MARKMAN, M ;

ROWINSKY, E ;

HAKES, T ;

REICHMAN, B ;

JONES, W ;

LEWIS, JL ;

RUBIN, S ;

CURTIN, J ;

BARAKAT, R ;

PHILLIPS, M ;

HUROWITZ, L ;

ALMADRONES, L ;

HOSKINS, W .

JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (09) :1485-1491

[32] 2ND-LINE PLATINUM THERAPY IN PATIENTS WITH OVARIAN-CANCER PREVIOUSLY TREATED WITH CISPLATIN [J].

MARKMAN, M ;

ROTHMAN, R ;

HAKES, T ;

REICHMAN, B ;

HOSKINS, W ;

RUBIN, S ;

JONES, W ;

ALMADRONES, L ;

LEWIS, JL .

JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (03) :389-393

[33]

Markman M, 1998, SEMIN ONCOL, V25, P356

[34] FOLLOW-UP OF THE ASYMPTOMATIC PATIENT WITH OVARIAN-CANCER [J].

MARKMAN, M .

GYNECOLOGIC ONCOLOGY, 1994, 55 (03) :S134-S137

[35] RESPONSES TO SALVAGE CHEMOTHERAPY IN OVARIAN-CANCER - A CRITICAL NEED FOR PRECISE DEFINITIONS OF THE TREATED POPULATION [J].

MARKMAN, M ;

HOSKINS, W .

JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (04) :513-514

[36] Tamoxifen in platinum-refractory ovarian cancer: A gynecologic oncology group ancillary report [J].

Markman, M ;

Iseminger, KA ;

Hatch, KD ;

Creasman, WT ;

Barnes, W ;

Dubeshter, B .

GYNECOLOGIC ONCOLOGY, 1996, 62 (01) :4-6

[37] OPTIMAL-CONTROL OF TUMOR SIZE USED TO MAXIMIZE SURVIVAL-TIME WHEN CELLS ARE RESISTANT TO CHEMOTHERAPY [J].

MARTIN, RB ;

FISHER, ME ;

MINCHIN, RF ;

TEO, KL .

MATHEMATICAL BIOSCIENCES, 1992, 110 (02) :201-219

[38] TAXOL - A UNIQUE ANTINEOPLASTIC AGENT WITH SIGNIFICANT ACTIVITY IN ADVANCED OVARIAN EPITHELIAL NEOPLASMS [J].

MCGUIRE, WP ;

ROWINSKY, EK ;

ROSENSHEIN, NB ;

GRUMBINE, FC ;

ETTINGER, DS ;

ARMSTRONG, DK ;

DONEHOWER, RC .

ANNALS OF INTERNAL MEDICINE, 1989, 111 (04) :273-279

[39]

McGuire WP, 1998, SEMIN ONCOL, V25, P340

[40] Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer [J].

McGuire, WP ;

Hoskins, WJ ;

Brady, MF ;

Kucera, PR ;

Partridge, EE ;

Look, KY ;

ClarkePearson, DL ;

Davidson, M .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (01) :1-6

← 1 2 3 4 5 6 7 8 →